donafenib: Clinical Trials

4 trials of donafenib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated. 4 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Completed 2, Terminated 2
Phase 22Completed 1, Terminated 1

Follow donafenib: new trials by email Literature Review of donafenib trials Research Report on donafenib

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
HAIC, TACE, FOLFOX - Hepatocellular Carcinoma
Phase 2 / Phase 3TerminatedPeking University182021-12-242025-12-18
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
Donafenib, Placebo - Differentiated Thyroid Cancer
Phase 3TerminatedSuzhou Zelgen Biopharmaceuticals Co.,Ltd2042018-08-292021-12-13
Donafenib for Previously Treated Metastatic Colorectal Cancer
Donafenib, Placebo - Metastatic Colorectal Cancer
Phase 3CompletedSuzhou Zelgen Biopharmaceuticals Co.,Ltd5362016-12-282022-11-29
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Donafenib, Sorafenib - HCC
Phase 2 / Phase 3CompletedSuzhou Zelgen Biopharmaceuticals Co.,Ltd6682016-03-012020-01-09

Conditions studied

Carcinoma, Hepatocellular (1)  ·  Colorectal Neoplasms (1)

Sponsors

Suzhou Zelgen Biopharmaceuticals Co.,Ltd (3)  ·  Peking University (1)

Countries

China (4)

Top investigators

Bi Feng, MD (1)  ·  Feng Bi, MD (1)  ·  Lin Yan Song, MD (1)  ·  Shukui Qin, MD (1)  ·  Xiaodong Wang, MD (1)  ·  Xu Jianming, MD (1)

Results publications

PMID 39924483, PMID 41163129